244 related articles for article (PubMed ID: 30905222)
1. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006-2015).
Kim JW; Lee CK; Lee JK; Jeong SJ; Oh SJ; Moon JR; Kim HS; Kim HJ
Scand J Gastroenterol; 2019 Apr; 54(4):419-426. PubMed ID: 30905222
[No Abstract] [Full Text] [Related]
2. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.
van der Valk ME; Mangen MJ; Severs M; van der Have M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk C; Vermeijden JR; Siersema PD; Leenders M; Oldenburg B;
PLoS One; 2016; 11(4):e0142481. PubMed ID: 27099937
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease.
Targownik LE; Benchimol EI; Witt J; Bernstein CN; Singh H; Lix L; Tennakoon A; Zubieta AA; Coward S; Jones J; Kuenzig E; Murthy SK; Nguyen GC; Peña-Sánchez JN; Kaplan G
Inflamm Bowel Dis; 2019 Sep; 25(10):1718-1728. PubMed ID: 31211836
[TBL] [Abstract][Full Text] [Related]
4. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.
Lawton J; Achit H; Pouillon L; Boschetti E; Demore B; Matton T; Tournier C; Prodel M; Peyrin-Biroulet L; Guillemin F
United European Gastroenterol J; 2019 Aug; 7(7):908-913. PubMed ID: 31428415
[TBL] [Abstract][Full Text] [Related]
5. Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
Niewiadomski O; Studd C; Hair C; Wilson J; McNeill J; Knight R; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Tacey M; Connell W; Desmond P; Bell S
J Crohns Colitis; 2015 Nov; 9(11):988-96. PubMed ID: 26129692
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
7. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
9. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
11. Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Lee J; Im JP; Han K; Kim J; Lee HJ; Chun J; Kim JS
Gut Liver; 2020 Jan; 14(1):89-99. PubMed ID: 31158951
[No Abstract] [Full Text] [Related]
12. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
Wilke T; Groth A; Long GH; Tatro AR; Sun D
Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
[TBL] [Abstract][Full Text] [Related]
13. The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.
Pillai N; Dusheiko M; Maillard MH; Rogler G; Brüngger B; Bähler C; Pittet VEH;
J Crohns Colitis; 2019 May; 13(6):744-754. PubMed ID: 30916775
[TBL] [Abstract][Full Text] [Related]
14. Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis.
Mak LY; Ng SC; Wong IOL; Li MKK; Lo FH; Wong MTL; Leung CM; Tsang SWC; Chan KH; Sze SF; Shan EHS; Lam BCY; Hui AJ; Hung IFN; Leung WK
J Gastroenterol Hepatol; 2018 Jan; 33(1):141-149. PubMed ID: 28475813
[TBL] [Abstract][Full Text] [Related]
15. Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow-up in a Danish Population-based Inception Cohort.
Lo B; Vind I; Vester-Andersen MK; Bendtsen F; Burisch J
J Crohns Colitis; 2020 Jan; 14(1):53-63. PubMed ID: 31076743
[TBL] [Abstract][Full Text] [Related]
16. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
[TBL] [Abstract][Full Text] [Related]
17. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population-based study.
Kim JW; Lee CK; Rhee SY; Oh CH; Shim JJ; Kim HJ
J Gastroenterol Hepatol; 2018 Apr; 33(4):847-854. PubMed ID: 29055148
[TBL] [Abstract][Full Text] [Related]
18. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
Martelli L; Olivera P; Roblin X; Attar A; Peyrin-Biroulet L
J Gastroenterol; 2017 Jan; 52(1):19-25. PubMed ID: 27665099
[TBL] [Abstract][Full Text] [Related]
20. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
